Novocure
Update in progressNVCR (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
NovoCure Limited is an oncology company that develops, manufactures, and commercializes tumor treating fields (TTFields) devices for solid tumor cancers. Its TTFields systems, including Optune Gio, Optune Lua, and Optune Pax, are sold in the United States, Germany, France, Japan, Greater China, and elsewhere. The company is pursuing TTFields trials for brain metastases, gastric, glioblastoma, liver, non-small cell lung, pancreatic, and ovarian cancers. Incorporated in 2000, it is headquartered in Baar, Switzerland.
Company score
- Sentiment
- 0.43
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.44
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationSwitzerland
- CEOMr. Frank Leonard
- Founded2000
- Employees1,605
- Websitewww.novocure.com
Identifiers
- ISINJE00BYSS4X48
- FIGIBBG009XW8PY2
- LEI213800YPP55UMHWA4826
- CUSIPG6674U108
- CIK0001645113